Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm

Journal of the American College of Cardiology

Volumn 41, Issue 1, 2003, Pages 15-19

  Mohri, Masahiro ^a   Shimokawa, Hiroaki ^a   Hirakawa, Yoji ^a   Masumoto, Akihiro ^a   Takeshita, Akira ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; CALCIUM ANTAGONIST; ENZYME INHIBITOR; FASUDIL; RHO KINASE;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY SPASM; DRUG EFFECT; DRUG POTENCY; ENZYME INHIBITION; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ACETYLCHOLINE; AGED; CARDIOVASCULAR AGENTS; CORONARY CIRCULATION; CORONARY VASOSPASM; ENZYME INHIBITORS; FEMALE; HEART FUNCTION TESTS; HUMANS; INFUSIONS, INTRA-ARTERIAL; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICROVASCULAR ANGINA; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PROTEIN-SERINE-THREONINE KINASES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 0037223388     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)02632-3     Document Type: Article

References (26)

1. Kaski JC, Rosano GMC, Collins P, Nihoyannopoulos P, Maseri A, Poole-Wilson PA. Cardiac syndrome X: Clinical characteristics and left ventricular function. A long-term follow-up study. J Am Coll Cardiol 1995;25:807-14.
2. Kaski JC, Elliott PM. Angina pectoris and normal coronary arteriograms: Clinical presentation and hemodynamic characteristics. Am J Cardiol 1995;76:35D-42D.
3. Cannon RO, Cunnion RE, Parrillo JE, Palmeri ST, Schenke WH, Epstein SE. Dynamic limitation of coronary vasodilator reserve in patients with dilated cardiomyopathy and chest pain. J Am Coll Cardiol 1987;10:1190-200.
4. Clarke JG, Davies GJ, Kerwin R, et al. Coronary artery infusion of neuropeptide Y in patients with angina pectoris. Lancet 1987;1:1057-9.
5. Mohri M, Koyanagi M, Egashira K, et al. Angina pectoris caused by coronary microvascular spasm. Lancet 1998;351:1165-9.
6. Somlyo AP, Somlyo AV. Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol 2000;522:177-85.
7. Shimokawa H. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J Cardiovasc Pharmacol 2002;39:319-27.
8. Shimokawa H, Seto M, Katsumata N, et al. Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc Res 1999;43:1029-39.
9. Kandabashi T, Shimokawa H, Miyata K, et al. Inhibition of myosin phosphatase by upregulated Rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1β. Circulation 2000;101:1319-23.
10. Masumoto A, Mohri M, Shimokawa H, Urakami L, Usui M, Takeshira A, Suppression of coronary artery spasm by the Rho-kinase inhibitor Fasudil in patients with vasospastic angina. Circulation 2002;105:1545-7.
11. Sun H, Mohri M, Shimokawa H, Usui M, Urakami L, Takeshita A. Coronary microvascular spasm causes myocardial ischemia in patients with vasospastic angina. J Am Coll Cardiol 2002;39:847-51.
12. Sugiishi M, Takatsu F. Cigarette smoking is a major risk factor for coronary spasm. Circulation 1993;87:76-9.
13. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000;351:95-105.
14. Kuga T, Egashira K, Mohri M, et al. Bradykinin-induced vasodilation is impaired at the atherosclerotic site but is preserved at the spastic site of human coronary arteries in vivo. Circulation 1995;92:183-9.
15. Tagawa T, Mohri M, Tagawa H, et al. Role of nitric oxide in substance P-induced vasodilation differs between the coronary and forearm circulation in humans. J Cardiovasc Pharmacol 1997;29:546-53.
16. Kaski JC, Valenzuela Garcia LF. Therapeutic options for the management of patents with cardiac syndrome X. Eur Heart J 2001;22:283-93.
17. Lanza GA, Colonna G, Pasceri V, Maseri A. Atenolol versus amlodipine versus isosorbide-5-mononitrate on anginal symptoms in syndrome X. Am J Cardiol 1999;84:854-6.
18. Masumoto A, Mohri M, Takeshita A. Three-year follow-up of the Japanese patients with microvascular angina attributable to coronary microvascular spasm. Int J Cardiol 2001;81:151-6.
19. Uehata M, Ishizaki T, Satoh H, et al. Calcium sensitization of smooth muscle mediated by a rho-associated protein kinase in hypertension. Nature 1997;389:990-4.
20. Masumoto A, Hirooka Y, Shimokawa H, Hironaga K, Setoguchi S, Takeshita A. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension 2001;38:1307-10.
21. 2+ sensitization of myosin phosphorylation and force in guinea-pig ileum. J Physiol 2000;522:33-49.
22. Batchelor TJ, Sadaba JR, Ishola A, Pacaud P, Munsch CM, Beech DJ. Rho-kinase inhibitors prevent agonist-induced vasospasm in human internal mammary artery. Br J Pharmacol 2001;132:302-8.
23. Katsumata N, Shimokawa H, Seto M, et al. Enhanced myosin light chain phosphorylations as a central mechanism for coronary artery spasm in a swine model with interleukin-1β. Circulation 1997;96:4357-63.
24. Golino P, Pisgione F, Benedict CR, et al. Local effect of serotonin released during coronary angioplasty. N Engl J Med 1994;330:523-8.
25. Sambuceti G, Marzilli M, Marraccini P, et al. Coronary vasoconstriction during myocardial ischemia induced by rises in metabolic demand in patients with coronary artery disease. Circulation 1997;95:2652-9.
26. Shimokawa H, Hiramori K, Iinuma H, et al. Antianginal effect of Fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: A multicenter study. J Cardiovasc Pharmacol 2002;40:751-61.